Liposomal Doxorubicin in Tanzania: NEMLIT level, who can prescribe it and STG references
Liposomal Doxorubicin is on Tanzania's National Essential Medicines List (NEMLIT, 7th edition, 2026) at level S (zonal, special and national hospitals). It is not on the DukaDawa pharmacy network yet, so we show no brands or prices for it. The Standard Treatment Guidelines mention it in 3 sections.
Last updated
New to DukadawaRx? Register as a prescriber. Licensed prescribers only; we verify your registration before you can prescribe.
Is liposomal Doxorubicin available on the DukaDawa pharmacy network?
Not yet. Liposomal Doxorubicin is not in the DukaDawa network catalogue, so we have no brands, prices or stock for it.
Prescribers can still write it on a DukadawaRx prescription, and we show it here as soon as a network pharmacy lists it.
Is liposomal Doxorubicin on the NEMLIT, and who can prescribe it?
Yes. Liposomal Doxorubicin is on Tanzania's National Essential Medicines List (NEMLIT, 7th edition, 2026) at level S (zonal, special and national hospitals). At level S it may be prescribed by specialists.
- Level
- S (zonal, special and national hospitals)
- Category
- Antineoplastics, Immunosuppressives and Immunomodulators
- Listed forms
- Injection: 2mg/ml, 5mg/ml
- Page
- NEMLIT, p. 13
| Level | Facility | Who may prescribe |
|---|---|---|
| A | Dispensary | Specialist, Medical Officer, Dental Officer, Assistant Medical Officer, Clinical Officer, Assistant Clinical Officer |
| B | Health centre | Specialist, Medical Officer, Dental Officer, Assistant Medical Officer, Clinical Officer |
| C | Council or district hospital | Specialist, Medical Officer, Dental Officer, Assistant Medical Officer |
| D | Regional referral hospital | Specialist, Medical Officer, Dental Officer |
| S (listed) | Zonal, special and national hospitals | Specialist |
A medicine is listed from the lowest facility level where it should be available.
Where is liposomal Doxorubicin in the Standard Treatment Guidelines?
The Standard Treatment Guidelines (7th edition, 2026) mention liposomal Doxorubicin in 3 sections, most often section 22.2.6 Gynecological Malignancies > Cancer of the Ovary (p. 578). See the STG for treatment details.
- 22.2.6 Gynecological Malignancies > Cancer of the Ovary, p. 578
- 22.4.3 Cancer of The Skin > Kaposi’s sarcoma (KS), p. 585
- 22.9.1.4 Haematological Malignancies > Lymphomas > Hodgkin’s disease (HD), p. 615
Sections that mention Liposomal Doxorubicin, most mentions first. Positions only: see the STG for treatment details.
Related medicines
- Abiraterone acetateNEMLIT S · Not on the DukaDawa network yet
- AdalimumabNEMLIT S · Not on the DukaDawa network yet
- AfliberceptNEMLIT S · Not on the DukaDawa network yet
- AlfuzosinNEMLIT D · Not on the DukaDawa network yet
- AllopurinolNEMLIT B · Not on the DukaDawa network yet
- AnastrozoleNEMLIT S · Not on the DukaDawa network yet
- Antithymocyte globulin (ATG) (rabbit)NEMLIT S · Not on the DukaDawa network yet
- AtezolizumabNEMLIT S · Not on the DukaDawa network yet
All antineoplastics, immunosuppressives and immunomodulators on the NEMLIT
Sources
- Standard Treatment Guidelines and National Essential Medicines List (STG/NEMLIT), 7th edition, 2026, Ministry of Health, United Republic of Tanzania
Page last updated
STG positions are section numbers and printed page numbers only.
This page supports licensed prescribers and pharmacists. It is not medical advice and does not replace the Standard Treatment Guidelines, the product information or professional judgement. Prices and stock change often: confirm with the pharmacy.